Xeris Pharmaceuticals, Inc., a specialty biotechnology firm that commercializes and develops ready-to-use (RTU) infusible and injectable drug formulations, has recently revealed topline results from its in-clinic stage Phase 2 trial of developmental RTU glucagon in patients that endure postprandial hypoglycemic episodes after bariatric surgery.

As per reports, the Phase 2 randomized, prospective, double-blind, placebo-controlled trial involved an in-clinic stage which was followed by a 12-week outpatient phase. Reportedly, the findings revealed that nearly every patient faced postprandial hypoglycemia within 90-120 minutes of their meals.

Amidst this successful meal challenge, it was also observed that patients were able to self-administer a small dosage of study drug, as prescribed while experiencing a shortage of blood glucose.

According to Paul R. Edick, Chairman and CEO, Xeris, the company is pleased with the results of the in-clinic phase of its PBH trial. The initial part of this trial marked as a significant step towards demonstrating the efficacy of stable, liquid, RTU glucagon in circumstances beyond rescue for acute hypoglycemia. It also showcased effectiveness and safety in events that demand self-administration by the patient.

He added that Xeris believes the remaining half of the trial, which isn’t controlled by the in-clinic environment, would positively proceed in demonstrating the mini dosing of RTU glucagon’s safety profile. This data would be accessible in the Q1-Q2 of 2020.

Prior to this news, Xeris Pharmaceuticals came into limelight when it revealed choosing Mark Thierer to be a part of its Board of Directors. This addition takes the board to seven members. Mr. Thierer would also become a participant of the Audit Committee.

Speaking of which, Mr. Edick commented that the company welcomes Mark Thierer and his immense experience & insights of this industry. As Xeris continues to grow into a commercial company, the firm is looking forward to partnering with Mark to design its strategic plans and further their vision.
 

Source Credit: https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-announces-positive-topline-results-clinic